The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

kit for the preparation of gallium-68 (68 Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging [1] agent for prostate cancer. Gozellix®, after radiolabeling with 68 Ga, is ...

Illuccix claims to be the first prostate-specific membrane antigen-positron emission tomography (PSMA-PET ... for preparing gallium-68 (⁶⁸Ga) gozetotide injection for PET imaging in conjunction with ...

This approval enables healthcare providers in the Netherlands to offer PSMA-PET imaging using a clinically validated gallium-based radiopharmaceutical ... largely replacing conventional imaging ...

It works by binding to cells that express PSMA, including malignant prostate ... Among the 100 patients with a negative gallium Ga 68 gozetotide PET scan, 84 were also negative based on ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation ...